Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.37 +3.3%	$4.20	$1.89 ▼ $5.82	$1.26B	0.65	5.46 million shs	3.27 million shs
CRSP CRISPR Therapeutics	$54.88 +1.4%	$55.23	$30.04 ▼ $71.13	$4.92B	1.8	2.93 million shs	1.28 million shs
MRUS Merus	$66.86 +1.7%	$60.44	$33.19 ▼ $68.18	$4.97B	1.09	571,521 shs	786,355 shs
TGTX TG Therapeutics	$28.28 -0.9%	$33.82	$21.11 ▼ $46.48	$4.53B	1.95	2.91 million shs	1.55 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-3.64%	-9.42%	-17.22%	+113.64%	+62.07%
CRSP CRISPR Therapeutics	-0.35%	-6.01%	-16.41%	+44.08%	+11.17%
MRUS Merus	-2.59%	-0.39%	-1.62%	+29.41%	+22.67%
TGTX TG Therapeutics	-3.09%	+2.88%	-22.68%	-19.04%	+16.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	1.6994 of 5 stars	3.5	1.0	0.0	0.6	3.3	0.0
CRSP CRISPR Therapeutics	3.6272 of 5 stars	4.3	3.0	0.0	2.2	3.3	0.6
MRUS Merus	2.3435 of 5 stars	3.5	1.0	0.0	3.4	2.5	0.0
TGTX TG Therapeutics	4.4047 of 5 stars	3.4	1.0	3.5	3.6	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.00	83.07% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	30.47% Upside
MRUS Merus	3.08	Buy	$88.75	32.74% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	63.54% Upside

Current Analyst Ratings Breakdown

Latest ABCL, MRUS, CRSP, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	MRUS Merus	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$90.00
8/25/2025	MRUS Merus	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$90.00
8/8/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	45.30	N/A	N/A	$3.37 per share	1.30
CRSP CRISPR Therapeutics	$37.31M	133.78	N/A	N/A	$18.81 per share	2.92
MRUS Merus	$36.13M	139.96	N/A	N/A	$11.13 per share	6.01
TGTX TG Therapeutics	$329M	13.64	$0.12 per share	237.82	$1.74 per share	16.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.55	N/A	N/A	N/A	-511.88%	-16.17%	-12.24%	11/3/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	10/30/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.37	76.43	28.28	N/A	13.31%	26.05%	9.58%	11/3/2025 (Estimated)

Latest ABCL, MRUS, CRSP, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	-$0.12	+$0.05	-$0.12	$7.55 million	$17.08 million
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	11.07	11.07
CRSP CRISPR Therapeutics	N/A	16.61	16.61
MRUS Merus	N/A	8.39	8.39
TGTX TG Therapeutics	0.89	3.86	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CRSP CRISPR Therapeutics	69.20%
MRUS Merus	96.14%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CRSP CRISPR Therapeutics	4.10%
MRUS Merus	3.70%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.83 million	212.47 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
MRUS Merus	37	75.63 million	72.84 million	Optionable
TGTX TG Therapeutics	290	158.67 million	141.78 million	Optionable

ABCL, MRUS, CRSP, and TGTX Headlines

Recent News About These Companies

Wellington Management Group LLP Boosts Position in TG Therapeutics, Inc. $TGTX

August 26 at 4:15 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Position Decreased by 1832 Asset Management L.P.

August 25 at 6:17 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Bought by Algert Global LLC

August 23 at 5:04 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Bought by Russell Investments Group Ltd.

August 23 at 4:26 AM | marketbeat.com

TG Therapeutics: Looking For The Stimulus For A Turnaround

August 20, 2025 | seekingalpha.com

Fox Run Management L.L.C. Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 19, 2025 | marketbeat.com

746,696 Shares in TG Therapeutics, Inc. $TGTX Bought by Nuveen LLC

August 19, 2025 | marketbeat.com

Invesco Ltd. Raises Position in TG Therapeutics, Inc. $TGTX

August 19, 2025 | marketbeat.com

Wealthedge Investment Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 17, 2025 | marketbeat.com

Sector Gamma AS Acquires Shares of 55,000 TG Therapeutics, Inc. (NASDAQ:TGTX)

August 17, 2025 | marketbeat.com

TG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You Think

August 16, 2025 | finance.yahoo.com

Aigen Investment Management LP Purchases Shares of 9,522 TG Therapeutics, Inc. (NASDAQ:TGTX)

August 14, 2025 | marketbeat.com

Persistent Asset Partners Ltd Has $1.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 13, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Public Sector Pension Investment Board

August 13, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Entropy Technologies LP

August 13, 2025 | marketbeat.com

Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 10, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

August 10, 2025 | marketbeat.com

TG Therapeutics files automatic mixed securities shelf

August 9, 2025 | msn.com

Beyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)

August 8, 2025 | gurufocus.com

What is B. Riley's Forecast for TG Therapeutics Q3 Earnings?

August 8, 2025 | marketbeat.com

B. Riley Has Bullish Outlook for TG Therapeutics Q4 Earnings

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, MRUS, CRSP, and TGTX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.37 +0.14 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 +0.03 (+0.69%)

As of 07:56 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

CRISPR Therapeutics NASDAQ:CRSP

$54.88 +0.75 (+1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$54.90 +0.02 (+0.04%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Merus NASDAQ:MRUS

$66.86 +1.12 (+1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$66.83 -0.03 (-0.04%)

As of 07:13 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

TG Therapeutics NASDAQ:TGTX

$28.28 -0.25 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$28.52 +0.24 (+0.87%)

As of 07:34 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time